Treatment-resistant depression: therapeutic trends, challenges, and future directions

Cited by (794)

Items 401–500 of 794

1. Using a machine learning approach to investigate factors associated with treatment-resistant depression among adults with chronic non-cancer pain conditions and major depressive disorder
   Drishti Shah, Wanhong Zheng, Lindsay Allen, Wenhui Wei, Traci LeMasters, Suresh Madhavan, Usha Sambamoorthi · 2021 · Current Medical Research and Opinion
2. Exploring CNS Effects of American Traditional Medicines using Zebrafish Models
   Allan V. Kalueff, Murilo S. de Abreu, Fabiano Costa, Ana C.V.V. Giacomini, Konstantin A. Demin, Elena V. Petersen, Denis Broock Rosemberg · 2021 · Current Neuropharmacology
3. Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials
   Mu‐Hong Chen, Hui-Ju Wu, Cheng‐Ta Li, Wei‐Chen Lin, Shih‐Jen Tsai, Chen‐Jee Hong, Pei‐Chi Tu, Ya‐Mei Bai, Wei‐Chung Mao, Tung‐Ping Su · 2021 · Journal of Psychiatric Research
4. A Brief, Individualized Exercise Program at Intensities Below the Ventilatory Threshold Exerts Therapeutic Effects for Depression: A Pilot Study
   Yuri Sakai, Chong Chen, Atsuhito Toyomaki, Naoki Hashimoto, Kan Kitagawa, Takao Inoue, Asumi Sato, Keisuke Makihara, Rie Kameyama, Yumi Wakatsuki et al. · 2021 · Frontiers in Behavioral Neuroscience
5. Modulation of Emotion Perception via Amygdala Stimulation in Humans
   Krzysztof A. Bujarski, Yinchen Song, Tiankang Xie, Zachary Leeds, Sophia I. Kolankiewicz, Gabriella H. Wozniak, Sean Anthony Guillory, Joshua P. Aronson, Luke J. Chang, Barbara C. Jobst · 2022 · Frontiers in Neuroscience
6. One-year incidence rate of Treatment Resistant Depression (TRD) and treatment characteristics in China
   Huaning Wang, Tina Wu, Sijia Dong, Muzhen Guan, Ao Liu, Kun Jiang, Rui Chi, Hong Xia Qiu, Wentian Dong, Tianmei Si · 2022 · Journal of Affective Disorders
7. Recent advances in the psychopharmacology of major depressive disorder
   Laith Alexander, Allan Hunter Young · 2022 · BJPsych Advances
8. Investigation of the underling mechanism of ketamine for antidepressant effects in treatment‑refractory affective disorders via molecular profile analysis
   Qiao, Jun, Sun, Yuan, Wu, Jinfang, Wang, Li · 2019 · Experimental and Therapeutic Medicine
9. Evaluation of the effect of insulin sensitivity-enhancing lifestyle- and dietary-related adjuncts on antidepressant treatment response: protocol for a systematic review and meta-analysis
   Olaitan J. Jeremiah, Gráinne Cousins, Finbarr P. Leacy, Brian P. Kirby, Benedict K. Ryan · 2019 · Systematic Reviews
10. Psychiatric Pharmacy: New Role of Pharmacists in Mental Health
    Abdul Kader Mohiuddin · 2019 · South Asian Research Journal of Pharmaceutical Sciences
11. Chronic ecologically relevant stress effects on reverse‐translated touchscreen assays of reward responsivity and attentional processes in male rats: Implications for depression
    Paloma Martinez Gonzalez, Amaya R. Jenkins, Kayleigh S. LaMalfa, Brian D. Kangas · 2024 · Journal of Neurochemistry
12. A novel butyrylcholinesterase inhibitor induces antidepressant, pro-cognitive, and anti-anhedonic effects in Flinders Sensitive Line rats: The role of the ghrelin-dopamine cascade
    Nadia Olivier, Brian Herbert Harvey, Stanislav Gobec, Mohammed Shahid, Urban Košak, Simon Žakelj, Christiaan Beyers Brink · 2025 · Biomedicine & Pharmacotherapy
13. Current drug targets for the treatment of depression
    Gauri Pathak, Aryaa Nigade, Kuttiappan Anitha, Shvetank Bhatt · 2025 · Brain Disorders
14. A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder
    Raúl Iván Escamilla-Orozco, María Eva González-Trujano, Jesús M. González Mariscal, Jesús Martín Torres-Valencia, Héctor Guzmán-González, José Luis Vega, Anja Katharina Loizaga-Velder · 2023 · Journal of Psychoactive Drugs
15. Evaluation of New Approaches to Depression Treatment Using an Animal Model of Pharmacoresistant Depression
    Alexandra Zvozilová, Stanislava Bukatová, Romana Koprdová, Mojmı́r Mach · 2024 · International Journal of Molecular Sciences
16. Unlocking new avenues for neuropsychiatric disease therapy: the emerging potential of Peroxisome proliferator-activated receptors as promising therapeutic targets
    Asmita Deka Dey, Ashi Mannan, Sonia Dhiman, Thakur Gurjeet Singh · 2024 · Psychopharmacology
17. Ethical Considerations for Clinical Research and Off-label Use of Ketamine to Treat Mood Disorders: The Balance Between Risks and Benefits
    Melvyn W. Zhang, Roger Ho · 2016 · Ethics & Behavior
18. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression
    Rachel Ochs-Ross, Ella Daly, Y. Zhang, Roseanne Lane, Pilar Lim, K. Foster, David W. Hough, Husseini K. Manji, Wayne Curtis Drevets, Gerard Sanacora et al. · 2019 · European Neuropsychopharmacology
19. Antidepressants In General Practice And Psychiatry
    Zoryana Lebedyn · 2020 · European Journal of Medical and Health Sciences
20. Characterization of antidepressant activity of Saraca asoca flower (Roxb.) Wilde in mice subjected to acute restraint stress.
    Shashikumara Shashikumara, Krishna Purushotham, C L Darshan, Bhuvanesh Sukhlal Kalal · 2022 · PubMed Central
21. Predicting Antidepressant Treatment Response Using Functional Brain Controllability Analysis
    Feng Zhou Fang, Beata R. Godlewska, Sudhakar Selvaraj, Yingchun Zhang · 2022 · Brain Connectivity
22. Setting national research priorities for difficult-to-treat depression in the UK between 2021-2026
    Natalya Chapman, Michael D Browning, David Baghurst, Matthew H. Hotopf, Debbie Willis, Stuart Haylock, Sana Zakaria, Jan Speechley, James R. Withey, Edmund Brooks et al. · 2022 · Journal of Global Health
23. Role of the Intestinal Microbiota in the Genesis of Major Depression and the Response to Antidepressant Drug Therapy: A Narrative Review
    Tiziana Mundula, Simone Baldi, Elisabetta Gerace, Amedeo Amedei · 2023 · Biomedicines
24. Vitamin D: An Anti-Inflammatory Treatment Option for Depression?
    Deborah Antai-Otong · 2014 · Issues in Mental Health Nursing
25. Psychopharmacological evaluation of antidepressant-like activity of ethanol seed extract of grains of paradise (Aframomum meleguetaK. Schum.)in mice
    Esther Toluwalope Ojo, Oritoke M. Aluko, Solomon Umukoro · 2018 · Journal of Food Biochemistry
26. Delayed increase of thrombocyte levels after a single sub-anesthetic dose of ketamine – A randomized trial
    Lejla Čolić, Marie Woelfer, Merima Čolić, Anna Linda Leutritz, Thomas Liebe, Luisa Fensky, Zümrüt Duygu Şen, Meng Li, Juliane Hoffmann, Moritz Kretzschmar et al. · 2018 · European Neuropsychopharmacology
27. Anhedonia as a basic syndrome and a target for treatment for depressive disorder
    Galina Elevna Mazo, Alexander O. Kibitov · 2019 · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
28. What Do We Know about Transcranial Direct Current Stimulation for Major Depression?
    Derrick Matthew Buchanan, Philippe Robaey, Amedeo D’Angiulli · 2020 · Brain Sciences
29. Synthesis and Evaluation of the Antidepressant-like Properties of HBK-10, a Novel 2-Methoxyphenylpiperazine Derivative Targeting the 5-HT1A and D2 Receptors
    Kinga Sałaciak, Natalia Malikowska‐Racia, Klaudia Lustyk, Agata Siwek, Monika Głuch‐Lutwin, Grzegorz Kazek, Justyna Popiół, Jacek Sapa, Henryk Marona, Dorota Żelaszczyk et al. · 2021 · Pharmaceuticals
30. Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug–Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression
    Maryia Zhdanava, Swapna U. Karkare, Dominic Pilon, Kruti Joshi, Carmine Rossi, Laura Morrison, John J. Sheehan, Patrick Lefèbvre, Oliver J. Lopena, Leslie Citrome · 2021 · Advances in Therapy
31. The Rise, Fall, and Resurgence of Electroconvulsive Therapy
    Anees Bahji · 2022 · Journal of Psychiatric Practice
32. Point-of-care companion diagnostic tests for personalizing psychiatric medications: fulfilling an unmet clinical need
    Anil S. Modak · 2017 · Journal of Breath Research
33. Obesity and Depression: Shared Pathophysiology and Translational Implications
    Lison Huet, Inês Delgado, Bruno Aouizerate, Nathalie Castanon, Lucile Capuron · 2019 · Elsevier eBooks
34. Integrated Long Noncoding RNA and Messenger RNA Expression Analysis Identifies Molecules Specifically Associated With Resiliency and Susceptibility to Depression and Antidepressant Response
    Qingzhong Wang, Huizhen Wang, Yogesh Dwivedi · 2024 · Biological Psychiatry Global Open Science
35. Nanoencapsulation of amitriptyline enhances the potency of antidepressant-like effects and exhibits anxiolytic-like effects in Wistar rats
    Ramón Eduardo Valadez-Lemus, José Luis Góngora-Alfaro, Juana María Jiménez-Vargas, Javier Alamilla, Néstor Mendoza‐Muñoz · 2025 · PLoS ONE
36. Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations
    Abhishek Sharma, Rahul Singh, Tarun Virmani, Neeraj Kumar Chouhan, Garima Kapoor, Girish Kumar, Rubina Bhutani, Neha Rana, Shivkant Sharma · 2025 · Naunyn-Schmiedeberg s Archives of Pharmacology
37. Measuring and appraising placebo effects in clinical trials: contemporary challenges and approaches in psychiatry
    Joseph J. Taylor, Balázs Szigeti, Noah D. Silverberg, Masoud Ahmadzad-Asl, Marina R. Kare, Ryan D. Webler, Diana K. Orsini, Joshua Daniel Rosenblat, Tom Bschor, Christopher Baethge et al. · 2026 · The Lancet Psychiatry
38. Depression, an unmet health need in Africa: Understanding the promise of ketamine
    Aletta M. E. Millen, Willie M. U. Daniels, Sooraj Baijnath · 2024 · Heliyon
39. Controlled ultrasonic interventions through the human skull
    Matthew G. Wilson, Thomas S. Riis, Jan Kubanek · 2024 · Frontiers in Human Neuroscience
40. Novel treatments of depression: bridging the gap in current therapeutic approaches
    Amit Jagtiani · 2024 · Exploration of neuroscience
41. A comparative study between two manufacturing processes for venlafaxine-loaded niosome (Nioven) production: optimization, characterization, pharmacokinetic investigations, depression management, and gene assessment
    Reza Enayatifard, Jafar Âkbari, Majid Saeedi, Mohammad Seyedabadi, Katayoun Morteza‐Semnani, Seyyed Mobin Rahimnia, Seyyed Mohammad Hassan Hashemi · 2025 · Journal of Dispersion Science and Technology
42. Brain connectivity correlates of the impact of a digital intervention for individuals with subjective cognitive decline on depression and IL-18
    M. Catalogna, Ya'ira Somerville, N. Saporta, Bar Nathansohn-Levi, S. Shelly, Liat Edry, O. Zagoory-Sharon, Ruth Feldman, A. Amedi · 2025 · Scientific Reports
43. From competition to co-operation: Shifting the “one best model” perspective
    Hannah Hawkins-Elder, Tony J. Ward · 2021 · Theory & Psychology
44. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration
    Michael D. Banov, Rachel E. Landrum, Michelle B. Moore, Steven T. Szabo · 2021 · Journal of Clinical Psychopharmacology
45. Electroencephalographic Signature of Negative Self Perceptions in Medical Students
    Richard Mark Millis, Justin A. Arcaro, Allison Palacios, Grace L Millis · 2022 · Cureus
46. Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions
    Annie McCartney, Hugh T. McGovern, Alexander De Foe · 2022 · Journal of Psychedelic Studies
47. Analyzing Turning Behavior after Repeated Lithium, Ketamine, or NaCl Injection and Chronic Stress Exposure in Mice
    Annakarina Mundorf, Hiroshi Matsui, Sebastian Ocklenburg, Nadja Freund · 2022 · Symmetry
48. Increased Brain-Derived Neurotrophic Factor and Hippocampal Dendritic Spine Density Are Associated with the Rapid Antidepressant-like Effect of Iron-citalopram and Iron-Imipramine Combinations in Mice
    Kennedy Kwami Edem Kukuia, Frederick B. Boakye, Kevin Kofi Adutwum-Ofosu, Frimpong Appiah, Seth Kwabena Amponsah, Richard Kofi Begyinah, Awo Efua Koomson, Yaw Takyi Ferka, Thomas Amatey Tagoe, Patrick Amoateng · 2023 · Neuroscience
49. Characterization of 2 Novel Phosphodiesterase 2 Inhibitors Hcyb1 and PF-05180999 on Depression- and Anxiety-Like Behavior
    Yuqing Yan, Yuhan Zhao, Yue Lu, Abhinav P. Acharya, Wei Wang, Chang‐Guo Zhan, Jianghong Ye, Fu Du, Xiongwei Zhu, Ying Xu · 2023 · The International Journal of Neuropsychopharmacology
50. The Utility of CYP2D6 and CYP2C19 Variants to Guide Pharmacological Treatment in Complex Unipolar Major Depression: A Pilot Longitudinal Study
    Reshma Ramaraj, Zeina N. Al-Mahayri, Reema Saleous, Karim Abdel Aziz, Fadwa Al Mugaddam, Mouza Al-Sabousi, Aysha Alhassani, Noura Ali Al Ahbabi, Émmanuel Stip, George P. Patrinos et al. · 2023 · Psychiatric Quarterly
51. Managing depression in frail older people; too little too late or pathologising loss?
    George J.E. Crowther, Sean G Ninan · 2023 · Future Healthcare Journal
52. Toward a Precision Treatment Approach for Metabolic Depression: Integrating Epidemiology, Neuroscience, and Psychiatry
    Kathleen T. Watson, Huda Akil, Natalie Rasgon · 2023 · Biological Psychiatry Global Open Science
53. Personal and perceived stigma in relation to diverse domains of quality of life among patients with major depressive disorder having residual symptoms: a hospital-based cross-sectional study in Thailand
    J. Pitanupong, W. Aunjitsakul · 2023 · Quality of Life Research
54. Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study
    A. Oliveira-Maia, B. Rive, Joachim Morrens, Y. Godinov, Jedelyn Cabrieto, N. Perualila, S. Mulhern-Haughey · 2023 · Frontiers in Psychiatry
55. Online mindfulness-based cognitive therapy for treatment-resistant depression: a parallel-arm randomized controlled feasibility trial
    Michele Ferreira Rodrigues, Laiana A. Quagliato, José Carlos Appolinário, Antônio Egídio Nardi · 2024 · Frontiers in Psychology
56. A partial least squares and artificial neural network study for a series of arylpiperazines as antidepressant agents
    Genisson R. Santos, Laise P. A. Chiari, Aldineia P. da Silva, Célio Fernando Lipinski, Aline Alves Oliveira, Kathia Maria Honorio, Alvaro S. de Sousa, Albérico B. F. da Silva · 2021 · Journal of Molecular Modeling
57. Emerging therapies for treatment resistant depression
    Ruki Wijesinghe · 2014 · Mental Health Clinician
58. A systematic review and meta-analysis of the preclinical and clinical results of low-field magnetic stimulation in cognitive disorders
    Nicholas Mellon, Brett Robbins, Rebekah van Bruggen, Yanbo Zhang · 2024 · Reviews in the Neurosciences
59. Ketamine and chronic treatment-resistant depression: real-world practice and after relapse
    Sumaya Jobnah, Youssef Latifeh, Dina Al Kabani, Lama A. Youssef · 2024 · BMC Psychiatry
60. Clinical Staging for Psychiatry and Psychology
    Dominic Dwyer, Rochelle Ruby Ye, Barnaby Nelson, Patrick D. McGorry · 2025 · Annual Review of Clinical Psychology
61. Implementation of a ketamine programme for treatment-resistant depression in the public health system: Lessons from the first Australian public hospital clinic
    Nicollette L. R. Thornton, Dean J. Wright, Nick Glozier · 2024 · Australian & New Zealand Journal of Psychiatry
62. Risk factors for suicidal attempts in a sample of outpatients with treatment-resistant depression: an observational study
    Serena Chiara Civardi, Filippo Besana, Giovanni Carnevale Miacca, Filippo Mazzoni, Vincenzo Arienti, Pierluigi Politi, Natascia Brondino, Miriam Olivola · 2024 · Frontiers in Psychiatry
63. Introduction to Emerging Technologies in Biomedical Sciences
    R. C. Sobti, Jagdish Rai, Anand Prakash · 2022 · Springer eBooks
64. Antidepressant-like Properties of Melatonin and Atorvastatin Combination following the Restraint Stress in Mice: A Study of Oxidative Stress Factors
    Vahid Nikoui, Azam Hosseinzadeh, Solmaz Javadi Khotab, Seyyedeh Zahra Mousavi, Meysam Abolmaali, Saeed Mehrzadi · 2022 · Central Nervous System Agents in Medicinal Chemistry
65. Association between the consumption of omega-3-rich fish and depressive symptoms in older adults living in a middle-income country: EpiFloripa Aging cohort study
    Gilciane Ceolin, Gabriele Rockenbach, Susana Cararo Confortin, Eleonora d’Orsi, Júlia Dübois Moreira · 2022 · Cadernos de Saúde Pública
66. Personality traits among major depressive disorder in southern Thailand: a hospital-based case–control study
    Jarurin Pitanupong, Adchara Sa-i · 2023 · BMC Psychology
67. The Antidepressant Activity of a Taurine-Containing Derivative of 4-Phenylpyrrolidone-2 in a Model of Chronic Unpredictable Mild Stress
    Denis A. Borozdenko, Darya I. Gonchar, Bogorodova V.I., Dmitri V. Tarasenko, Evgeniya P. Kramarova, Svetlana S. Khovanova, Yaroslav V. Golubev, Nina M. Kiseleva, Tatiana Anatolievna Shmigol, Aiarpi A. Ezdoglian et al. · 2023 · International Journal of Molecular Sciences
68. Recent advances on the role of pro-inflammatory cytokine interleukin-18 in post-stroke depression
    Yutong Zhang, Hao Li, Zeheng Li, Shuming Yang, Dan Niu, Yi Yang, Xingshun Xu · 2023 · Brain Behavior and Immunity Integrative
69. A review of the prescribing culture of anti-depressants across government districts in Northern Ireland
    Mark W. Ruddock, Joanne Watt, Mary Jo Kurth, John V. Lamont, Laura Mooney, Peter S. FitzGerald · 2023 · Frontiers in Drug Safety and Regulation
70. Study to determine the epidemiology of treatment-resistant depression among the Saudi Arabian population: A cross-sectional study
    Abdullah S. Alshehri, Abdullah Mohammed Algarni, Hussein Ahmed M. Almahdi, Abdulkhaliq Hadi H. Asiri, Hassan Yahya M. Asiri, Ahmad Abdullah H. Alsulami, Hassan Ahmed A. Alasiri, Nawaf Khalid Ahmad Hassan · 2023 · Journal of Education and Health Promotion
71. Creative, person-centered and narrative psychopharmacotherapy or how to prevent and overcome treatment resistance in psychiatry.
    Miro Jakovljević · 2015 · PubMed
72. The antidepressant-like activity of chiral xanthone derivatives may be mediated by 5-HT1A receptor and β-arrestin signalling
    Kinga Sałaciak, Monika Głuch‐Lutwin, Agata Siwek, Małgorzata Szafarz, Grzegorz Kazek, Marek Bednarski, Leszek Nowiński, Emma J. Mitchell, Magdalena Jastrzębska‐Więsek, Anna Partyka et al. · 2020 · Journal of Psychopharmacology
73. Problem Solving Therapy Improves Effortful Cognition in Major Depression
    Chenguang Jiang, Hongliang Zhou, Limin Chen, Zhenhe Zhou · 2021 · Frontiers in Psychiatry
74. Differences in Cerebral Distribution between Imipramine and Paroxetine via Membrane Transporters at the Rat Blood-Brain Barrier
    Shin‐ichi Akanuma, Myeongrae Han, Yuka Murayama, Yoshiyuki Kubo, Ken‐ichi Hosoya · 2022 · Pharmaceutical Research
75. How Far Has Repetitive Transcranial Magnetic Stimulation Come Along in Treating Patients With Treatment-Resistant Depression?
    Jake Vogel, Varun Soti · 2022 · Cureus
76. The combination of mirtazapine plus venlafaxine reduces immobility in the forced swim test and does not inhibit female sexual behavior
    Adriana Álvarez Silva, Alonso Fernández‐Guasti · 2019 · Pharmacology Biochemistry and Behavior
77. Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
    Madison N. Irwin, Amy VandenBerg · 2021 · Mental Health Clinician
78. Association between timing of adjunctive brexpiprazole initiation and healthcare resource use and costs in major depressive disorder
    Shivanshu Awasthi, Dusica Hadzi Boskovic, Shivani Kapadia · 2025 · Journal of Medical Economics
79. Evaluation of the first nutritional psychiatry and psychosomatics outpatient clinic: Protocol for a prospective study of an individualized biopsychosocial therapy approach
    Sabrina Mörkl, Anna Ramirez-Obermayer, Birgit DelFabro, Sonja Lackner, Sandra Johanna Holasek, Julia Traub, Katharina Größbacher, Andreas Brandstätter, Marilena Wilding, Jolana Wagner‐Skacel · 2026 · PLoS ONE
80. Omega-3 fatty acids in mental disorders: from neurobiological and metabolic mechanisms to therapeutic potential
    Katharina Fleig, Leoni Haslinger, Christine Dawczynski, Iris‐Tatjana Kolassa · 2026 · Frontiers in Nutrition
81. The clinical & economic burden of treatment‐resistant depression in the Gulf‐Cooperation Council: The Kingdom of Saudi Arabia, Kuwait and the United Arab Emirates
    Aly Akram, Medhat Al‐Sabahy, Ahmed H. Al-Jedai, Hajer Almudaiheem, Mohamed Farghally, Ebtihaj Omar Fallata, Osama A. Alibrahim, Tarek M. Shoukry, Sujata Basu, D Chalouhi et al. · 2022 · International Journal of Methods in Psychiatric Research
82. Long-Term Effects of Single and Repeated Ketamine Infusions on Treatment-Resistant Depression: A Retrospective Chart Review Study
    Sofia Sakopoulos, Lisa D. Hinz · 2024 · Psychoactives
83. Electroconvulsive Therapy Changes Peripheral Blood Neurotrophic and Inflammatory Markers in Depressed Patients
    Nadia Falhani, Lisa-Marie Brunner, Doris Melchner, Jens Volkmar Schwarzbach, Rainer Rupprecht, Caroline Nothdurfter · 2025 · Journal of Ect
84. Role of Dietary Polyphenols in NAD+-Dependent Deacetylase SIRT 1 in Stress-Induced Depression
    Nicole Less, Fúlvio Rieli Mendes, Giulio Maria Pasinetti · 2025 · Molecular Neurobiology
85. The role of Zinc Intake in Serotonin and Cortisol Level in Patient with Depression
    Tanjung Ayu Sumekar, Innawati Jusup, Natalia Dewi Wardani, Titis Hadiati, Mohammad Sulchan, Alifiati Fitrikasari · 2022 · Journal of Biomedicine and Translational Research
86. Influence and Selection of Probiotics on Depressive Disorders in Occupational Health: Scoping Review
    José Antonio Picó-Monllor, Elena Sala-Segura, Romina A. Tobares, Avelina Moreno-Ochando, Adrián Hernández-Teruel, Vicente Navarro‐López · 2023 · Nutrients
87. The Effects of Remifentanil, Dexmedetomidine, and Metoral as Adjuncts to Thiopental on Hemodynamic Status After Electroconvulsive Therapy in Patients with Major Depressive Disorder: A Randomized Controlled Clinical Trial
    Nastaran Tajabadi, Alireza Kamali, Anita Alaghmand, Hamidreza Jamilian, Shirin Pazooki, Amin Tajerian · 2023 · Anesthesiology and Pain Medicine
88. New insights about the antidepressant-like effects of riparin A in a chronic murine model of depression
    Cássio Prinholato da Silva, Denise Dias Oliveira, Bruno Iglesias Benincasa, Bruna Barbar, Raphaela Gonçalves Barros Perri, Ana Lúcia Fachin, Luiz Luciano Falconi‐Sobrinho, René Oliveira Beleboni · 2024 · Behavioural Pharmacology
89. Problem Solving in Dance/Movement Therapy Research: Developing an Intervention Protocol for Adults Living with Treatment Resistant Depression
    Neha Christopher · 2024 · American Journal of Dance Therapy
90. Concept article: Antidepressant‐induced destabilization in bipolar illness mediated by serotonin 3 receptor (5HT3)
    İrem Hacısalihoğlu Aydın, Rif S. El‐Mallakh · 2024 · Bipolar Disorders
91. Effects of an acute maximal exercise bout on serum insulin-like growth factor-1 in adults with MDD
    Shania J.E. Kelly, Jacob Meyer, Christiane Stielow, Stephan Heinzel, Andreas Heißel · 2024 · Psychoneuroendocrinology
92. Prediction of pharmacological treatment efficacy using electroencephalography-based salience network in patients with major depressive disorder
    Kang‐Min Choi, Taegyeong Lee, Chang‐Hwan Im, Seung‐Hwan Lee · 2024 · Frontiers in Psychiatry
93. Self-criticism predicts antidepressant effects of intermittent theta-burst stimulation in Major Depressive Disorder
    Aliya Jomha, Myren N. Sohn, Molly Watson, Daniel C. Kopala‐Sibley, Alexander McGirr · 2024 · Journal of Affective Disorders
94. Cognitive Behavioral Therapy and Behavioral Activation Therapy for Treatment-Resistant Depression: Traditional and Digital Therapy Perspectives
    Jennifer Apolinário-Hagen, Lara Fritsche, Liesemarie Albers, Christel Salewski · 2018 · Springer eBooks
95. Design and Development of a Behaviorally Active Recombinant Neurotrophic Factor
    Nicholas J. Pekas, Jason L. Petersen, Monica Sathyanesan, Samuel Sathyanesan Newton · 2020 · Drug Design Development and Therapy
96. Early Improvement with Vortioxetine Predicts Response and Remission: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan
    Takeshi Inoue, Shinji Fujimoto, Tatsuro Marumoto, T Kitagawa, Kazuyuki Ishida, Tadashi Nakajima, Yoshiya Moriguchi, Keita Fujikawa, Koichiro Watanabe · 2021 · Neuropsychiatric Disease and Treatment
97. Dietary inflammation score is associated with perceived stress, depression, and cardiometabolic health risk factors among a young adult cohort of women
    Rachel O. Knight, Yenni E. Cedillo, Suzanne E. Judd, Stephanie E. Tison, Elizabeth H. Baker, Douglas R. Moellering · 2022 · Clinical Nutrition ESPEN
98. Addressing depressive disorders among people with HIV.
    Andres Fuenmayor, Francine Cournos · 2022 · PubMed Central
99. ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry
    Albino Jorge Oliveira-Maia, Joachim Morrens, Benoît Rive, Yordan Godinov, Jedelyn Cabrieto, Nolen Joy Perualila, S. Barbreau, Siobhán Mulhern-Haughey · 2023 · Frontiers in Psychiatry
100. A Retrospective Case–Control Study on the Differences in the Effectiveness of Theta-Burst Stimulation Therapy for Depression with and without Antidepressant Medication
     Haruki Ikawa, Yuya Takeda, Ryota Osawa, Akiko Sato, Hoshimi Mizuno, Yoshihiro Noda · 2024 · Journal of Clinical Medicine